MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia. [PDF]
Oncogene, 2017 In 11q23 leukemias, the N-terminal part of the mixed lineage leukemia (MLL) gene is fused to >60 different partner genes. In order to define a core set of MLL rearranged targets, we investigated the genome-wide binding of the MLL-AF9 and MLL-AF4 fusion ...
Prange KHM +8 more
europepmc +2 more sources
Fetal liver Mll-AF4+ hematopoietic stem and progenitor cells respond directly to poly(I:C), but not to a single maternal immune activation. [PDF]
Exp Hematol, 2019 Highlights • Poly(I:C) and LPS promote the proliferation of fetal Mll-AF4+ B-lymphoid cells.• Poly(I:C) is a positive regulator of the Mll-AF4 expression signature.• A single maternal immune activation does not induce Mll-AF4+ leukemia.• The Mll-AF4 ...
Malouf C, Ottersbach K.
europepmc +2 more sources
The fetal liver lymphoid-primed multipotent progenitor provides the prerequisites for the initiation of t(4;11) <i>MLL-AF4</i> infant leukemia. [PDF]
Haematologica, 2018 t(4;11) MLL-AF4 pro-B acute lymphoblastic leukemia (ALL) is an aggressive hematologic malignancy that accounts for 50-85% of infant ALL cases. Retrospective analysis of Guthrie cards and twin concordance studies both confirmed the pre-natal origin of ...
Malouf C, Ottersbach K.
europepmc +2 more sources
Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras. [PDF]
Blood Adv, 2018 Infant B-cell acute lymphoblastic leukemias (B-ALLs) that harbor MLL-AF4 rearrangements are associated with a poor prognosis. One important obstacle to progress for this patient population is the lack of immunocompetent models that faithfully ...
Chu SH +13 more
europepmc +2 more sources
Clinical characteristics and prognostic analysis of different fusion gene abnormalities in childhood acute lymphoblastic leukaemia [PDF]
Frontiers in OncologyObjectiveThis study aimed to analyze the clinical features and prognostic significance of different fusion gene subtypes in pediatric patients with acute lymphoblastic leukaemia (ALL).MethodsClinical data from 132 childhood patients with ALL diagnosed ...
Rui Fan +9 more
doaj +2 more sources
Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL [PDF]
Molecular Cancer Therapeutics, 2018 MLL-rearranged acute lymphoblastic leukemia (ALL) occurring in infants is a rare but very aggressive leukemia, typically associated with a dismal prognosis.
M. Bardini +16 more
semanticscholar +4 more sources
MLL-AF4+ infant leukemia: a microRNA affair. [PDF]
Blood, 2021 J. Schwaller
semanticscholar +3 more sources
P314: THERAPEUTICALLY TARGETING THE UNIQUE BARCODE OF MLL/AF4
HemaSphere, 2022 R. Cameron +3 more
doaj +2 more sources
MLL-AF4, a double-edged sword for iPSC respecification into HSPCs. [PDF]
Proc Natl Acad Sci U S A, 2018 The successful derivation of human embryonic stem cells (hESCs) in 1998 (1) and later of induced pluripotent stem cells (iPSCs) in 2006/2007 (2, 3) led to huge excitement and held great promise to revolutionize several fields, from basic research to regenerative and personalized medicine, as these human pluripotent cells (hPSCs) have the potential when
Zeisig BB, So CWE.
europepmc +4 more sources
Functional Studies of MLL-AF4 and a Murinized pSer-variant thereof: MLL-AF4 Impairs the Ribosome Biosynthesis Pathway [PDF]
, 2021 Abstract Background: Recent pathomolecular studies on the MLL-AF4 fusion protein revealed that the murinized version of MLL-AF4, the MLL-Af4 fusion protein, was able to induce leukemia when expressed in murine or human hematopoietic stem/progenitor cells (1).
Anna Lena Siemund +2 more
openaire +1 more source